Related Experiment Video
Updated: Apr 18, 2026
08:16
Author Spotlight: Advancing Type 1 Diabetes Research Using Innovative Pancreatic Slice Platforms
Published on: March 15, 2024
2.4K
Future artificial pancreas technology for type 1 diabetes: what do users want?
Katharine D Barnard1, Jordan E Pinsker, Nick Oliver
11 Human Development and Health, Faculty of Medicine, University of Southampton , Southampton, United Kingdom .
Diabetes Technology & Therapeutics
|January 29, 2015
Summary
People with type 1 diabetes strongly desire artificial pancreas (AP) technology to reduce disease burden and improve quality of life, despite concerns about device effectiveness and appearance.
Area of Science:
- Diabetes technology
- Artificial pancreas systems
- Patient-centered research
Background:
- Artificial pancreas (AP) research has predominantly focused on technical metrics like glucose control.
- Limited research has explored user expectations for AP technology in type 1 diabetes management.
Purpose of the Study:
- To investigate the expectations and future use intentions of individuals with type 1 diabetes regarding artificial pancreas technology.
- To gather user perspectives to inform the development of AP devices that meet user needs.
Main Methods:
- An online survey was distributed to individuals with type 1 diabetes and parents of children with type 1 diabetes.
- Survey data, including Likert scale responses and free text, were collected and analyzed using content analysis.
Main Results:
- A high likelihood of using a fully automated 24-hour AP was reported by 240 participants.
- Concerns regarding size, visibility, and effectiveness were primary deterrents for some users.
- Participants emphasized the need for APs to alleviate disease burden and enhance psychosocial well-being and quality of life.
Conclusions:
- User perspectives are critical for developing successful and usable artificial pancreas technology.
- Integrating user needs with technical advancements is essential for APs to achieve their intended goals and gain user acceptance.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:12Type I Diabetes I: Introduction
1
Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1...
1
01:16Insulin: Dosing Regimen and Adverse Effects
1.3K
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:22Diabetes Mellitus: Overview and Type I Subtype
6.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
6.4K
01:26Type I Diabetes II: Pathophysiology
1
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular...
1